Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term, Open-label, Low-interventional Safety Study of Inebilizumab in the Treatment of NMOSD (N-MOmentum LT)

NCT06180278 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06180278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06180278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term, Open-label, Low-interventional Safety Study of Inebilizumab in the Treatment of NMOSD (N-MOmentum LT)
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Active, not recruiting
Start date
April 2, 2024
Completion date
June 26, 2028
Enrollment
32 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorder